Trial Profile
A Phase 1 Dose-Finding Study Of The Anti-Angiogenesis Agent AG-013736, In Combinations Of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, Gemcitabine/Cisplatin and Pemetrexed/Cisplatin In Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2019
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Capecitabine; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Solid tumours
- Focus Adverse reactions
- 11 Jan 2019 Results characterizing the physiological and molecular characteristics driving variability in axitinib AUCSS using physiologically based pharmacokinetic modeling using data from Pfizer trials (A4061019, A406010, A4061022, A4061036, A4061044, A4061055, A406105) published in the Journal of Clinical Pharmacology
- 26 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Nov 2010 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.